First RSV Vaccine on The Horizon – Pfizer Touts Strong Trial Results

Pfizer plans to ask the Food and Drug Administration to authorize an RSV vaccine “designed to protect infants” by the end of the year, the company said, citing “strong results” from late-stage clinical trials.

A single shot given during the late second to third trimester of pregnancy was “highly effective” at protecting newborns during their first months of life, the company said.

“The shot was nearly 82% effective at preventing a severe form of lower respiratory tract illness from RSV during the baby’s first 90 days of life”, Pfizer said.

“No safety concerns for parents or children were identified during the trial and the vaccine was well-tolerated” Pfizer said.